Adaptive Biotechnologies Corp
NASDAQ:ADPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adaptive Biotechnologies Corp
Operating Income
Adaptive Biotechnologies Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
Operating Income
-$57.1m
|
CAGR 3-Years
34%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Operating Income
$8.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Operating Income
$5.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Waters Corp
NYSE:WAT
|
Operating Income
$800.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Operating Income
$1.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Operating Income
$2.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
Adaptive Biotechnologies Corp
Glance View
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.
See Also
What is Adaptive Biotechnologies Corp's Operating Income?
Operating Income
-57.1m
USD
Based on the financial report for Dec 31, 2025, Adaptive Biotechnologies Corp's Operating Income amounts to -57.1m USD.
What is Adaptive Biotechnologies Corp's Operating Income growth rate?
Operating Income CAGR 5Y
18%
Over the last year, the Operating Income growth was 63%. The average annual Operating Income growth rates for Adaptive Biotechnologies Corp have been 34% over the past three years , 18% over the past five years .
